The Broad Institute in Cambridge, Mass., will retain potentially lucrative rights to a powerful gene-editing technique that could lead to major advances in medicine and agriculture, the federal Patent and Trademark Office ruled on Wednesday.

The decision, in a bitterly fought dispute closely watched by scientists and the biotechnology industry, was a blow to the University of California, often said to be the birthplace of the technique, which is known as Crispr-Cas9.

An appeals board of the patent office ruled that the gene-editing inventions claimed by the two institutions were separate and do not overlap.